Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytoDyn Inc.CYDY · Entity 5856 | CFO | January 03, 2024 | January 06, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytoDyn Inc.
Report date January 03, 2024 · Filed January 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.03 · Expires 2030-01-16 | Direct | 0 |
Reported balance
After 2024-01-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-03 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: The outstanding option was cancelled in exchange for a new option having a lower exercise price. F1: The option was fully vested and exercisable prior to January 3, 2024. |
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.10 · Expires 2030-02-21 | Direct | 0 |
Reported balance
After 2024-01-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-03 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: The outstanding option was cancelled in exchange for a new option having a lower exercise price. F1: The option was fully vested and exercisable prior to January 3, 2024. |
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.57 · Expires 2030-07-22 | Direct | 0 |
Reported balance
After 2024-01-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-01-03 · Disposition to issuer · Disposed 100,000 · Balance 0 F2: The outstanding option was cancelled in exchange for a new option having a lower exercise price. F1: The option was fully vested and exercisable prior to January 3, 2024. |
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.54 · Expires 2031-02-17 | Direct | 0 |
Reported balance
After 2024-01-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-01-03 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: The outstanding option was cancelled in exchange for a new option having a lower exercise price. F3: Vesting was scheduled to occur in three equal annual installments beginning on February 17, 2022. |
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.32 · Expires 2031-08-06 | Direct | 0 |
Reported balance
After 2024-01-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-01-03 · Disposition to issuer · Disposed 1,000,000 · Balance 0 F2: The outstanding option was cancelled in exchange for a new option having a lower exercise price. F4: Vesting was scheduled to occur in three equal annual installments beginning on August 6, 2022. |
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.58 · Expires 2032-09-20 | Direct | 0 |
Reported balance
After 2024-01-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-01-03 · Disposition to issuer · Disposed 630,222 · Balance 0 F2: The outstanding option was cancelled in exchange for a new option having a lower exercise price. F5: 25% of the award vested on January 24, 2023, with the balance scheduled to vest in 36 equal monthly installments, subject to Continuous Service (as the term is defined in the Issuer's 2012 Equity Incentive Plan, as amended) through the applicable vesting date. |
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.21 · Expires 2030-01-16 | Direct | 50,000 |
Reported balance
After 2024-01-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-01-03 · Grant · Acquired 50,000 · Balance 50,000 F2: The outstanding option was cancelled in exchange for a new option having a lower exercise price. |
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.21 · Expires 2030-02-21 | Direct | 50,000 |
Reported balance
After 2024-01-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-01-03 · Grant · Acquired 50,000 · Balance 50,000 F2: The outstanding option was cancelled in exchange for a new option having a lower exercise price. |
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.21 · Expires 2030-07-22 | Direct | 100,000 |
Reported balance
After 2024-01-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-01-03 · Grant · Acquired 100,000 · Balance 100,000 F2: The outstanding option was cancelled in exchange for a new option having a lower exercise price. |
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.21 · Expires 2031-02-17 | Direct | 50,000 |
Reported balance
After 2024-01-03 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-01-03 · Grant · Acquired 50,000 · Balance 50,000 F2: The outstanding option was cancelled in exchange for a new option having a lower exercise price. F6: 33,300 shares were fully vested and exercisable on January 3, 2024; the balance is scheduled to vest on February 17, 2024. |
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.21 · Expires 2031-08-06 | Direct | 1,000,000 |
Reported balance
After 2024-01-03 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2024-01-03 · Grant · Acquired 1,000,000 · Balance 1,000,000 F2: The outstanding option was cancelled in exchange for a new option having a lower exercise price. F7: 666,000 shares were fully vested and exercisable on January 3, 2024; the balance is scheduled to vest on August 6, 2024. |
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.21 · Expires 2032-09-20 | Direct | 630,222 |
Reported balance
After 2024-01-03 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2024-01-03 · Grant · Acquired 630,222 · Balance 630,222 F2: The outstanding option was cancelled in exchange for a new option having a lower exercise price. F8: 301,975 shares were fully vested and exercisable on January 3, 2024; the balance will vest in equal monthly installments at the conclusion of each month of Continuous Service beginning at the end of January 2024 through January 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was fully vested and exercisable prior to January 3, 2024.
F2: The outstanding option was cancelled in exchange for a new option having a lower exercise price.
F3: Vesting was scheduled to occur in three equal annual installments beginning on February 17, 2022.
F4: Vesting was scheduled to occur in three equal annual installments beginning on August 6, 2022.
F5: 25% of the award vested on January 24, 2023, with the balance scheduled to vest in 36 equal monthly installments, subject to Continuous Service (as the term is defined in the Issuer's 2012 Equity Incentive Plan, as amended) through the applicable vesting date.
F6: 33,300 shares were fully vested and exercisable on January 3, 2024; the balance is scheduled to vest on February 17, 2024.
F7: 666,000 shares were fully vested and exercisable on January 3, 2024; the balance is scheduled to vest on August 6, 2024.
F8: 301,975 shares were fully vested and exercisable on January 3, 2024; the balance will vest in equal monthly installments at the conclusion of each month of Continuous Service beginning at the end of January 2024 through January 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2024 Filed Jan 6, 2024 02:04 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified stock option (right to buy) · Derivative | 630,222 | Not disclosed Strike: $0.21 | Not disclosed |
DisclosureSEC source: 0001104659-24-001956 · tm242134-7_4seq1.xml · derivative · entry 12 Migliarese Antonio · CIK 0001864040 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 630,222 Underlying: Common Stock · 630,222 shares Expires 2032-09-20 F2 · price: The outstanding option was cancelled in exchange for a new option having a lower exercise price. F8 · derivative.exercise_date: 301,975 shares were fully vested and exercisable on January 3, 2024; the balance will vest in equal monthly installments at the conclusion of each month of Continuous Service beginning at the end of January 2024 through January 2026. Read SEC document |
| January 03, 2024 Filed Jan 6, 2024 02:04 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified stock option (right to buy) · Derivative | 1,000,000 | Not disclosed Strike: $0.21 | Not disclosed |
DisclosureSEC source: 0001104659-24-001956 · tm242134-7_4seq1.xml · derivative · entry 11 Migliarese Antonio · CIK 0001864040 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2031-08-06 F2 · price: The outstanding option was cancelled in exchange for a new option having a lower exercise price. F7 · derivative.exercise_date: 666,000 shares were fully vested and exercisable on January 3, 2024; the balance is scheduled to vest on August 6, 2024. Read SEC document |
| January 03, 2024 Filed Jan 6, 2024 02:04 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified stock option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $0.21 | Not disclosed |
DisclosureSEC source: 0001104659-24-001956 · tm242134-7_4seq1.xml · derivative · entry 10 Migliarese Antonio · CIK 0001864040 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-02-17 F2 · price: The outstanding option was cancelled in exchange for a new option having a lower exercise price. F6 · derivative.exercise_date: 33,300 shares were fully vested and exercisable on January 3, 2024; the balance is scheduled to vest on February 17, 2024. Read SEC document |
| January 03, 2024 Filed Jan 6, 2024 02:04 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified stock option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $0.21 | Not disclosed |
DisclosureSEC source: 0001104659-24-001956 · tm242134-7_4seq1.xml · derivative · entry 9 Migliarese Antonio · CIK 0001864040 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-07-22 F2 · price: The outstanding option was cancelled in exchange for a new option having a lower exercise price. Read SEC document |
| January 03, 2024 Filed Jan 6, 2024 02:04 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified stock option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $0.21 | Not disclosed |
DisclosureSEC source: 0001104659-24-001956 · tm242134-7_4seq1.xml · derivative · entry 8 Migliarese Antonio · CIK 0001864040 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-02-21 F2 · price: The outstanding option was cancelled in exchange for a new option having a lower exercise price. Read SEC document |
| January 03, 2024 Filed Jan 6, 2024 02:04 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified stock option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $0.21 | Not disclosed |
DisclosureSEC source: 0001104659-24-001956 · tm242134-7_4seq1.xml · derivative · entry 7 Migliarese Antonio · CIK 0001864040 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-01-16 F2 · price: The outstanding option was cancelled in exchange for a new option having a lower exercise price. Read SEC document |
| January 03, 2024 Filed Jan 6, 2024 02:04 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerNon-qualified stock option (right to buy) · Derivative | 630,222 | Not disclosed Strike: $0.58 | Not disclosed |
DisclosureSEC source: 0001104659-24-001956 · tm242134-7_4seq1.xml · derivative · entry 6 Migliarese Antonio · CIK 0001864040 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 630,222 shares Expires 2032-09-20 F2 · price: The outstanding option was cancelled in exchange for a new option having a lower exercise price. F5 · derivative.exercise_date: 25% of the award vested on January 24, 2023, with the balance scheduled to vest in 36 equal monthly installments, subject to Continuous Service (as the term is defined in the Issuer's 2012 Equity Incentive Plan, as amended) through the applicable vesting date. Read SEC document |
| January 03, 2024 Filed Jan 6, 2024 02:04 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerNon-qualified stock option (right to buy) · Derivative | 1,000,000 | Not disclosed Strike: $1.32 | Not disclosed |
DisclosureSEC source: 0001104659-24-001956 · tm242134-7_4seq1.xml · derivative · entry 5 Migliarese Antonio · CIK 0001864040 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000,000 shares Expires 2031-08-06 F2 · price: The outstanding option was cancelled in exchange for a new option having a lower exercise price. F4 · derivative.exercise_date: Vesting was scheduled to occur in three equal annual installments beginning on August 6, 2022. Read SEC document |
| January 03, 2024 Filed Jan 6, 2024 02:04 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerNon-qualified stock option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $5.54 | Not disclosed |
DisclosureSEC source: 0001104659-24-001956 · tm242134-7_4seq1.xml · derivative · entry 4 Migliarese Antonio · CIK 0001864040 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2031-02-17 F2 · price: The outstanding option was cancelled in exchange for a new option having a lower exercise price. F3 · derivative.exercise_date: Vesting was scheduled to occur in three equal annual installments beginning on February 17, 2022. Read SEC document |
| January 03, 2024 Filed Jan 6, 2024 02:04 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerNon-qualified stock option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $5.57 | Not disclosed |
DisclosureSEC source: 0001104659-24-001956 · tm242134-7_4seq1.xml · derivative · entry 3 Migliarese Antonio · CIK 0001864040 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2030-07-22 F2 · price: The outstanding option was cancelled in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option was fully vested and exercisable prior to January 3, 2024. Read SEC document |
| January 03, 2024 Filed Jan 6, 2024 02:04 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerNon-qualified stock option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $1.10 | Not disclosed |
DisclosureSEC source: 0001104659-24-001956 · tm242134-7_4seq1.xml · derivative · entry 2 Migliarese Antonio · CIK 0001864040 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2030-02-21 F2 · price: The outstanding option was cancelled in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option was fully vested and exercisable prior to January 3, 2024. Read SEC document |
| January 03, 2024 Filed Jan 6, 2024 02:04 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerNon-qualified stock option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $1.03 | Not disclosed |
DisclosureSEC source: 0001104659-24-001956 · tm242134-7_4seq1.xml · derivative · entry 1 Migliarese Antonio · CIK 0001864040 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2030-01-16 F2 · price: The outstanding option was cancelled in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option was fully vested and exercisable prior to January 3, 2024. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 01:34 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 12,008 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-123366 · tm2231600-4_4seq1.xml · nonDerivative · entry 1 Migliarese Antonio · CIK 0001864040 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,207 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| November 28, 2022 Filed Dec 1, 2022 01:34 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified stock option (right to buy) · Derivative | 4,585,536 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001104659-22-123366 · tm2231600-4_4seq1.xml · derivative · entry 2 Migliarese Antonio · CIK 0001864040 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,585,536 Underlying: Common Stock · 4,585,536 shares Expires 2032-11-28 F2 · derivative.exercise_date: 477,660 shares vested on November 28, 2022; the balance will vest in equal monthly installments at the conclusion of each month of Continuous Service (as the term is defined in the Issuer's 2012 Equity Incentive Plan, as amended) from November 2022 through May 2026. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 23:53 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 10,807 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-119981 · tm2230762-3_4seq1.xml · nonDerivative · entry 1 Migliarese Antonio · CIK 0001864040 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,199 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| October 31, 2022 Filed Nov 3, 2022 00:55 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 12,714 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-114100 · tm2228860-3_4seq1.xml · nonDerivative · entry 1 Migliarese Antonio · CIK 0001864040 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,392 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| October 15, 2022 Filed Oct 18, 2022 20:03 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 9,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-109690 · tm2228392-2_4seq1.xml · nonDerivative · entry 1 Migliarese Antonio · CIK 0001864040 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,678 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 23:14 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 10,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-105981 · tm2227293-2_4seq1.xml · nonDerivative · entry 1 Migliarese Antonio · CIK 0001864040 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,854 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| September 20, 2022 Filed Sep 23, 2022 00:21 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified stock option (right to buy) · Derivative | 630,222 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001104659-22-102417 · tm2226067-5_4seq1.xml · derivative · entry 1 Migliarese Antonio · CIK 0001864040 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 630,222 Underlying: Common Stock · 630,222 shares Expires 2032-09-20 F1 · derivative.exercise_date: 25% of the award will vest on January 24, 2023; thereafter, the balance will vest in 36 equal monthly installments, subject to Continuous Service (as the term is defined in the Issuer's 2012 Equity Incentive Plan, as amended) through the applicable vesting date. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 23:30 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 7,086 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-101256 · tm2226067-2_4seq1.xml · nonDerivative · entry 1 Migliarese Antonio · CIK 0001864040 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,562 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| August 31, 2022 Filed Sep 2, 2022 23:59 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 8,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-097604 · tm2221304-8_4seq1.xml · nonDerivative · entry 1 Migliarese Antonio · CIK 0001864040 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,476 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 20:02 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 5,208 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-092173 · tm2221304-4_4seq1.xml · nonDerivative · entry 1 Migliarese Antonio · CIK 0001864040 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,163 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| July 31, 2022 Filed Aug 4, 2022 20:09 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 5,614 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-086125 · tm2222420-2_4seq1.xml · nonDerivative · entry 1 Migliarese Antonio · CIK 0001864040 · CFO & Interim President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,955 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 20:02 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 9,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-080837 · tm2221304-2_4seq1.xml · nonDerivative · entry 1 Migliarese Antonio · CIK 0001864040 · CFO & Interim President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,341 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 21:16 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 10,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-077435 · tm2220248-2_4seq1.xml · nonDerivative · entry 1 Migliarese Antonio · CIK 0001864040 · CFO & Interim President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,517 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| June 15, 2022 Filed Jun 21, 2022 20:48 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 10,807 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-073010 · tm2218921-2_4seq1.xml · nonDerivative · entry 1 Migliarese Antonio · CIK 0001864040 · CFO & Interim President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,225 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| May 31, 2022 Filed Jun 8, 2022 20:05 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 13,509 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-069294 · tm2217755-1_4seq1.xml · nonDerivative · entry 5 Migliarese Antonio · CIK 0001864040 · CFO & Interim President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,448 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| May 15, 2022 Filed Jun 8, 2022 20:05 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 12,714 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-069294 · tm2217755-1_4seq1.xml · nonDerivative · entry 4 Migliarese Antonio · CIK 0001864040 · CFO & Interim President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,939 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| April 30, 2022 Filed Jun 8, 2022 20:05 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 13,509 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-069294 · tm2217755-1_4seq1.xml · nonDerivative · entry 3 Migliarese Antonio · CIK 0001864040 · CFO & Interim President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,225 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| April 15, 2022 Filed Jun 8, 2022 20:05 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 16,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-069294 · tm2217755-1_4seq1.xml · nonDerivative · entry 2 Migliarese Antonio · CIK 0001864040 · CFO & Interim President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,716 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| March 31, 2022 Filed Jun 8, 2022 20:05 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 11,683 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-069294 · tm2217755-1_4seq1.xml · nonDerivative · entry 1 Migliarese Antonio · CIK 0001864040 · CFO & Interim President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,706 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:19 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified stock option (right to buy) · Derivative | 1,000,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0000899243-21-032387 · doc4.xml · derivative · entry 2 Migliarese Antonio · CIK 0001864040 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common stock · 1,000,000 shares Expires 2031-08-06 F2 · derivative.exercise_date: The option vests in three equal annual installments beginning on August 6, 2022. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:19 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon stock | 3,023 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-032387 · doc4.xml · nonDerivative · entry 1 Migliarese Antonio · CIK 0001864040 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,023 F1 · shares: Represents shares received in lieu of 50% of a cash incentive bonus paid for services performed during the fiscal year ended May 31, 2021, which may be paid (a) 100% in cash or (b) 50% in stock and 50% in cash, as determined by the issuer's compensation committee of the board of directors. F1 · price: Represents shares received in lieu of 50% of a cash incentive bonus paid for services performed during the fiscal year ended May 31, 2021, which may be paid (a) 100% in cash or (b) 50% in stock and 50% in cash, as determined by the issuer's compensation committee of the board of directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.